Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
LUMO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.22
N/A
-0.98
vs -0.68
Q1.23
N/A
-0.89
vs -0.92
Q2.23
N/A
-1.09
vs -0.94
Q3.23
N/A
-1.04
vs -0.86
Q4.23
N/A
-1.17
vs -0.98
Q1.24
N/A
-1.29
vs -0.89
Q2.24
N/A
-0.93
vs -1.09
Q3.24
N/A
-0.90
vs -1.04
Q4.24
N/A
-0.67
vs -1.17
Q1.25
N/A
-0.38
vs -1.29
Sales Growth
YoY
Current
Estimates
Q4.22
+133%
512K vs 220K
Q1.23
+523%
691K vs 111K
Q2.23
+31%
527K vs 403K
Q3.23
-99%
7K vs 497K
Q4.23
+61%
826K vs 512K
Q1.24
-76%
165K vs 691K
Q2.24
-7%
488K vs 527K
Q3.24
+10271%
726K vs 7K
Q4.24
-46%
443.3K vs 826K
Q1.25
-9%
150K vs 165K
Return on Equity
QoQ
Q4.22
-13%
-0.13
vs -0.11
Q1.23
-13%
-0.13
vs -0.13
Q2.23
-20%
-0.20
vs -0.13
Q3.23
-23%
-0.23
vs -0.20
Q4.23
-35%
-0.35
vs -0.23
Q1.24
-60%
-0.60
vs -0.35
Q2.24
-73%
-0.73
vs -0.60
Q3.24
-152%
-1.52
vs -0.73
Institutionnal Ownership
QoQ
Q1.23
34
34
vs 37
-8%
Q2.23
34
34
vs 34
NA
Q3.23
33
33
vs 34
-3%
Q4.23
37
37
vs 33
12%
Q1.24
35
35
vs 37
-5%
Q2.24
35
35
vs 35
NA
Q3.24
28
28
vs 35
-20%
Q4.24
1
1
vs 28
-96%
globenewswire.com
14 hours ago
prnewswire.com
15 hours ago
prnewswire.com
15 hours ago
Quote Panel
Key Metrics
Forecast
93%2025-Revenue
-112%2025-EPS
82%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
H.C. Wainwright
downgradePrevious: Not converted
2024-10-24
Now: Neutral
EF Hutton
initialisePrevious: Not converted
2024-09-24
Now: Buy
Jefferies
downgradePrevious: Not converted
2022-11-14
Now: Hold
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
After-hours 0.00$-4.34 (-100.00%)
Relative Strenght
84
Volume Buzz
280%
Earning Acce
Yes
Dist 52w H.
5%Relative Strength
LUMO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
